Catalyst Pharmaceuticals, Inc. (CPRX)
NASDAQ: CPRX · Real-Time Price · USD
23.37
+0.61 (2.68%)
At close: May 9, 2025, 4:00 PM
22.99
-0.38 (-1.63%)
After-hours: May 9, 2025, 7:40 PM EDT

Company Description

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States.

It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy.

The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets.

Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals logo
Country United States
Founded 2002
IPO Date Nov 8, 2006
Industry Biotechnology
Sector Healthcare
Employees 181
CEO Richard John Daly

Contact Details

Address:
355 Alhambra Circle, Suite 801
Coral Gables, Florida 33134
United States
Phone 305 420 3200
Website catalystpharma.com

Stock Details

Ticker Symbol CPRX
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001369568
CUSIP Number 14888U101
ISIN Number US14888U1016
SIC Code 2834

Key Executives

Name Position
Richard John Daly M.B.A. President, Chief Executive Officer and Director
Michael W. Kalb CPA Executive Vice President, Treasurer and Chief Financial Officer
Dr. Steven R. Miller Ph.D. Executive Vice President, Chief Operating Officer and Chief Scientific Officer
Jeffrey Del Carmen Executive Vice President and Chief Commercial Officer
Dr. Preethi Sundaram Ph.D. Chief Strategy Officer
Mary Coleman Vice President and Head of Investor Relations
Brian Elsbernd J.D. Chief Compliance Officer and Chief Legal Officer
Gregg Russo Chief Human Resources Officer
Dr. Gary Ingenito M.D., Ph.D. Chief Medical and Regulatory Officer
Dr. Stanley Iyadurai M.D., Ph.D. Senior Vice President of Medical Affairs and Drug Discovery

Latest SEC Filings

Date Type Title
May 7, 2025 8-K Current Report
May 7, 2025 10-Q Quarterly Report
Apr 28, 2025 SCHEDULE 13G/A Filing
Apr 14, 2025 ARS Filing
Apr 11, 2025 DEF 14A Other definitive proxy statements
Apr 9, 2025 8-K Current Report
Mar 6, 2025 144 Filing
Mar 5, 2025 144 Filing
Mar 3, 2025 144 Filing
Mar 3, 2025 144 Filing